Get the Stockscreener App
13.36
0.68%
0.09
Pre-market:
13.60
0.24
+1.80%
Alvotech stock is traded at $13.36, with a volume of 151.38K.
It is up +0.68% in the last 24 hours and up +12.17% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
See More
Previous Close:
$13.27
Open:
$13.16
24h Volume:
151.38K
Relative Volume:
1.26
Market Cap:
$4.03B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-7.2216
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
+0.38%
1M Performance:
+12.17%
6M Performance:
+11.89%
1Y Performance:
-5.52%
1-Day Range:
$13.05
$13.44
1-Week Range:
$13.05
$13.50
52-Week Range:
$9.15
$18.00
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
13.36 | 4.03B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Alvotech : Transactions of Managers and Closely Associated Persons - Marketscreener.com
Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Alvotech (NASDAQ:ALVO) Sees Large Growth in Short Interest - MarketBeat
Alvotech (NASDAQ:ALVO) Shares Gap UpWhat's Next? - MarketBeat
Alvotech birtir fjárhagsdagatal fyrir árið 2025 - GlobeNewswire
Alvotech Eyes Growth As Product Revenue Soars And New Launches ApproachWill The Stock Follow? - RTTNews
Are Medical Stocks Lagging Alvotech (ALVO) This Year? - Yahoo Finance
Alvotech (NASDAQ:ALVO) Short Interest Update - MarketBeat
Alvotech Joins Nasdaq Biotechnology Index, Boosting Industry Presence - TipRanks
Alvotech : Added to Nasdaq Biotech Index Effective Monday December 23, 2024 Form 6 K - Marketscreener.com
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - The Manila Times
Alvotech Secures Coveted Spot in Nasdaq Biotechnology Index Following Strong Market Performance - StockTitan
ALVOAlvotech Ordinary Shares Latest Stock News & Market Updates - StockTitan
Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade - MSN
Alvotech's SWOT analysis: biosimilar powerhouse stock faces b2b model challenges - Investing.com
Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year? - MSN
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration - The Center for Biosimilars
Alvotech (NASDAQ:ALVO) Is Expected To Breakeven In The Near Future - Simply Wall St
Short Interest in Alvotech (NASDAQ:ALVO) Rises By 47.8% - MarketBeat
Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com
Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com
Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha
Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN
Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance
Earnings call: Alvotech reported revenues of $128 million - Investing.com India
Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada
Alvotech Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada
Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Alvotech earnings missed, revenue fell short of estimates - Investing.com India
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia
Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com
Alvotech Showcases Strong Financial Growth and Expansion - TipRanks
Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times
Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire
Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):